Clinical Trials
139 trialsNCT00087685 2025-05-01
RAD001 in Recurrent Endometrial Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00113360 2025-05-01
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00449748 2025-05-01
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00942734 2025-05-01
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03173560 2025-04-01
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
Phase 2 Completed
NCT03659136 2025-02-24
The XENERAâ„¢ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Boehringer Ingelheim
Phase 2 Completed
NCT02531932 2025-02-19
Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02216786 2024-12-02
MANTA
Queen Mary University of London
Phase 2 Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01678664 2024-09-25
EVACEL
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02228681 2024-09-19
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT02155920 2024-05-08
Everolimus for Children With Recurrent or Progressive Ependymoma
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02456857 2024-02-13
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03312738 2024-01-23
BOLERO-5
Novartis
Phase 2 Completed
NCT02332902 2023-12-20
DCLNF1
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed
NCT01298713 2023-09-06
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT02028364 2023-08-24
PEARL
Jules Bordet Institute
Phase 2 Completed
NCT00255788 2023-08-04
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02333565 2023-05-25
CEVOREM
Assistance Publique Hopitaux De Marseille
Phase 2 Completed
NCT01698918 2023-05-03
BOLERO-4
Novartis
Phase 2 Completed
NCT02915783 2023-01-17
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Eisai Inc.
Phase 2 Completed
NCT01642186 2022-12-29
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00805129 2022-11-25
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00830895 2022-11-09
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
Seoul National University Hospital
Phase 2 Completed
NCT03163667 2022-09-15
ENTRATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT02049047 2022-09-10
ONC-2010-001
Istituto Clinico Humanitas
Phase 2 Completed
NCT01229943 2022-08-04
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00886691 2022-02-04
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT01399918 2022-02-01
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00805961 2021-12-08
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00591734 2021-11-24
RAD001 Plus Bevacizumab in Metastatic Melanoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01665768 2021-10-26
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00936858 2021-10-22
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02742051 2021-09-23
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT02451696 2021-09-01
A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
NYU Langone Health
Phase 2 Completed
NCT01931163 2021-07-20
NECTAR
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00702052 2021-05-25
PILLAR-1
Novartis
Phase 2 Completed
NCT01563354 2021-04-02
LUNA
Novartis
Phase 2 Completed
NCT01929642 2021-03-29
RAPT
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT01231659 2021-03-26
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Novartis
Phase 2 Completed
NCT01783444 2021-02-26
BOLERO-6
Novartis
Phase 2 Completed
NCT00827359 2021-02-24
Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01270321 2021-02-17
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Emory University
Phase 2 Completed
NCT01051570 2020-12-01
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01059318 2020-11-19
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Novartis
Phase 2 Completed
NCT02113800 2020-10-28
EVINEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT02283658 2020-10-23
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Mayo Clinic
Phase 2 Completed
NCT02201212 2020-09-16
Everolimus for Cancer With TSC1 or TSC2 Mutation
Dana-Farber Cancer Institute
Phase 2 Completed